3 hours ago
1
Shidlovski/iStock via Getty Images
Viatris (NASDAQ:VTRS) shares fell in the premarket on Friday after the company announced that its experimental therapy for blepharitis, an inflammatory condition of the eyelids, did not reach the main goal in a late-stage trial.
Citing data from its MR-139
English (US) ·